AML Expanded Dx (UK) at Chughtai Lab

AML Expanded Dx (UK) at Chughtai Lab

Acute Myeloid Leukemia (AML) is a highly heterogeneous and aggressive hematological malignancy characterized by the rapid clonal expansion of immature myeloid progenitor cells in the bone marrow and peripheral blood. Over the past decade, the clinical management of AML has undergone a paradigm shift, transitioning from a purely morphologic and cytochemical classification to a highly sophisticated molecular and genetic framework. The AML Expanded Dx (UK) at Chughtai Lab represents a state-of-the-art molecular diagnostic panel designed to perform comprehensive genomic profiling of AML patients. By utilizing advanced molecular technologies, including Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR), this panel identifies critical somatic mutations, insertions, deletions, and gene fusions that define the unique molecular signature of an individual’s leukemia.

The diagnostic value of the AML Expanded Dx (UK) panel lies in its ability to consolidate multiple essential genetic assays into a single, streamlined workflow. Historically, clinicians had to order sequential single-gene tests, which not only consumed precious diagnostic tissue but also delayed the initiation of targeted therapies. This expanded panel evaluates a broad spectrum of clinically actionable genes and prognostic markers, aligning with the latest international guidelines, such as the European LeukemiaNet (ELN) and the World Health Organization (WHO) classifications. Understanding the specific genetic alterations present in a patient’s leukemia is paramount for establishing an accurate diagnosis, determining long-term prognosis, and formulating an individualized, risk-adapted treatment strategy.

At Chughtai Lab, this advanced molecular investigation is conducted under strict quality control protocols, leveraging cutting-edge genomic infrastructure and the expertise of highly qualified molecular pathologists and hematologists. The panel evaluates key anatomical and cellular structures, specifically focusing on the genomic DNA and RNA extracted from malignant myeloblasts. By identifying specific driver mutations and clonal architectures, the AML Expanded Dx (UK) panel empowers oncologists and hematologists across Pakistan to deliver precision medicine, optimizing therapeutic efficacy while minimizing unnecessary treatment-related toxicities.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure the integrity of the biological specimen and the accuracy of the molecular analysis. Patients undergoing the AML Expanded Dx (UK) panel should adhere to the following guidelines:

• Consultation and Documentation: Patients must provide a complete clinical history, including previous complete blood count (CBC) reports, bone marrow aspirate findings, and details of any prior chemotherapy or immunosuppressive treatments. A formal referral from a consultant hematologist or oncologist is highly recommended.
• Fasting Requirements: There are no strict fasting requirements for a peripheral blood draw. However, if the sample is to be collected via a bone marrow aspiration and biopsy under conscious sedation, the patient may be instructed to fast for 4 to 6 hours prior to the procedure.
• Medication Review: Patients must inform their healthcare provider of all current medications, particularly anticoagulants or antiplatelet agents (such as aspirin, clopidogrel, or warfarin), which may need to be temporarily discontinued prior to a bone marrow biopsy to minimize the risk of bleeding.
• Transfusion History: It is critical to notify the laboratory if the patient has received a blood transfusion or a stem cell transplant recently, as circulating donor DNA can interfere with the sensitivity and specificity of the molecular genetic analysis.
• Hydration: Adequate hydration is encouraged prior to peripheral blood collection, as it facilitates easier venous access and ensures a smooth phlebotomy experience.

During the Procedure

The AML Expanded Dx (UK) panel can be performed on either a peripheral blood sample or a bone marrow aspirate sample, depending on the clinical scenario and the treating physician’s recommendation. The procedure details for both methods are outlined below:

• Peripheral Blood Collection: If peripheral blood is used, a trained phlebotomist at Chughtai Lab will perform a standard venipuncture. The skin over the selected vein is thoroughly cleansed with an antiseptic solution. A sterile needle is inserted, and blood is drawn into specialized EDTA tubes designed to preserve genomic DNA and RNA. The procedure takes approximately 5 to 10 minutes and is associated with minimal discomfort.
• Bone Marrow Aspiration: If a bone marrow sample is required, the procedure is performed by a qualified hematologist in a sterile clinical setting. The skin overlying the posterior superior iliac spine is cleaned and draped. A local anesthetic is injected to numb the skin and the bone’s surface. A specialized bone marrow aspiration needle is then advanced into the marrow cavity, and a small volume of liquid bone marrow is drawn into a syringe. The procedure is generally well-tolerated and completed within 20 to 30 minutes.
• Post-Procedure Care: Following a peripheral blood draw, gentle pressure is applied to the puncture site, and a small bandage is placed. For bone marrow aspiration, a sterile pressure dressing is applied to the site, and the patient is advised to rest for a short period and avoid strenuous physical activity for the remainder of the day.
• Specimen Transport: Once collected, the specimen is immediately labeled with unique patient identifiers and transported to Chughtai Lab’s specialized molecular diagnostics division under controlled temperature conditions to prevent nucleic acid degradation.

When is a AML Expanded Dx (UK) Performed?

Suspected Acute Myeloid Leukemia Diagnosis

The primary clinical indication for performing the AML Expanded Dx (UK) panel is when a patient presents with clinical signs, symptoms, and initial laboratory findings highly suggestive of Acute Myeloid Leukemia. Common clinical presentations include severe fatigue, unexplained weight loss, persistent fevers, recurrent infections, easy bruising, and petechiae. Initial blood tests often reveal marked cytopenias or leukocytosis with circulating myeloblasts. When these abnormalities are detected, the molecular panel is initiated to confirm the diagnosis at a genetic level, ruling out other clonal hematological disorders and establishing the precise molecular subtype of AML.

Risk Stratification and Prognostication

AML is characterized by highly variable clinical outcomes, largely driven by the underlying genetic mutations within the leukemic clones. Physicians request the AML Expanded Dx (UK) panel at the time of initial diagnosis to perform molecular risk stratification. By analyzing mutations in genes such as NPM1, CEBPA, FLT3, TP53, and RUNX1, the panel categorizes patients into favorable, intermediate, or adverse risk groups according to the European LeukemiaNet (ELN) guidelines. This risk stratification is critical, as it dictates whether a patient can be successfully treated with standard chemotherapy alone or if they require an early allogeneic hematopoietic stem cell transplant (HSCT) during their first complete remission.

Selection of Targeted Therapies

The landscape of AML therapeutics has evolved to include several highly effective targeted agents. The AML Expanded Dx (UK) panel is performed to identify actionable genetic mutations that make a patient eligible for these specific therapies. For example, the detection of FLT3-ITD or FLT3-TKD mutations guides the addition of FLT3 inhibitors (such as midostaurin or gilteritinib) to the treatment regimen. Similarly, identifying IDH1 or IDH2 mutations allows for the potential use of targeted IDH inhibitors (such as ivosidenib or enasidenib). Identifying these mutations early ensures that patients receive the most effective, personalized therapeutic combinations from the outset of their treatment.

Monitoring Treatment Response and Minimal Residual Disease (MRD)

Following the initiation of induction chemotherapy, the AML Expanded Dx (UK) panel is utilized to monitor the patient’s response to treatment. While conventional microscopy can confirm morphological remission (less than 5% blasts in the bone marrow), it lacks the sensitivity to detect low levels of residual leukemia. By tracking specific molecular markers identified at baseline (such as NPM1 mutations or specific gene fusions), this highly sensitive panel can detect Minimal Residual Disease (MRD) down to one leukemic cell in tens of thousands of healthy cells. Monitoring MRD helps clinicians assess the depth of remission, predict early relapse, and adjust consolidation therapies accordingly.

Evaluation of Relapsed or Refractory AML

In cases where AML does not respond to initial therapy (refractory disease) or returns after a period of remission (relapsed disease), the molecular profile of the leukemia can change due to clonal evolution. Under the selective pressure of chemotherapy, new genetic mutations may emerge, or minor subclones may become dominant. Performing the AML Expanded Dx (UK) panel at the time of relapse or progression is essential to re-evaluate the genetic landscape of the disease. This allows oncologists to identify new therapeutic targets, understand mechanisms of drug resistance, and select appropriate salvage therapies or clinical trials for the patient.

What Does a AML Expanded Dx (UK) Detect?

The AML Expanded Dx (UK) panel is designed to detect a comprehensive array of genetic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and key gene rearrangements. The specific molecular findings detected by this panel include:

• FLT3-ITD Mutations: Internal tandem duplications in the FLT3 gene, indicating adverse prognosis if present in high allelic ratios.
• FLT3-TKD Mutations: Point mutations in the tyrosine kinase domain of the FLT3 gene, serving as targets for FLT3 inhibitors.
• NPM1 Mutations: Insertions in exon 12 of the NPM1 gene, generally conferring a favorable prognosis in the absence of FLT3-ITD.
• Biallelic CEBPA Mutations: Double mutations in the CEBPA gene, associated with favorable clinical outcomes.
• IDH1 Mutations: Recurrent mutations in the IDH1 gene (typically at codon R132), serving as a target for ivosidenib.
• IDH2 Mutations: Mutations in the IDH2 gene (typically at codons R140 or R172), targetable with enasidenib.
• TP53 Mutations: Alterations in the TP53 tumor suppressor gene, strongly associated with complex karyotypes and chemotherapy resistance.
• RUNX1 Mutations: Mutations in the RUNX1 gene, classified under the adverse-risk category.
• ASXL1 Mutations: Epigenetic regulator mutations associated with older age and adverse prognosis.
• DNMT3A Mutations: Mutations in the DNA methyltransferase 3 alpha gene, influencing epigenetic regulation.
• TET2 Mutations: Loss-of-function mutations in the TET2 gene, affecting DNA demethylation.
• KIT Mutations: Mutations in the KIT receptor tyrosine kinase, relevant in core-binding factor AML.
• WT1 Mutations: Mutations or overexpression of the Wilms Tumor 1 gene, useful for minimal residual disease monitoring.
• PHF6 Mutations: Tumor suppressor mutations frequently mutated in aggressive myeloid neoplasms.
• EZH2 Mutations: Mutations in the EZH2 gene, associated with poor prognosis.
• KMT2A (MLL) Rearrangements: Structural variants involving the KMT2A gene, defining specific biological subtypes.
• BCOR Mutations: Mutations in the BCL6 corepressor gene, associated with adverse clinical outcomes.
• STAG2 Mutations: Cohesin complex mutations that contribute to chromosomal instability.
• U2AF1 Mutations: Spliceosome machinery mutations characteristic of AML with myelodysplasia-related changes.
• SRSF2 Mutations: Spliceosome mutations associated with advanced age and chronic myelomonocytic leukemia transformation.

Turnaround Time and Report Access at Chughtai Lab

The AML Expanded Dx (UK) panel is a highly specialized, high-complexity molecular diagnostic test. Because it involves sophisticated next-generation sequencing, bioinformatics analysis, and expert clinical interpretation, the turnaround time for this panel is typically 10 to 14 working days. Chughtai Lab is committed to delivering highly accurate and reliable results within the shortest possible timeframe, recognizing the critical nature of these findings for oncology patients.

Once the analysis is complete, the molecular pathology report undergoes a rigorous multi-step verification process by consultant molecular pathologists and hematologists. Patients and their referring physicians are notified immediately via SMS when the report is finalized. Reports can be accessed and downloaded online through the official Chughtai Lab website or via the Chughtai Active Mobile App. Physical copies of the report can also be collected from any Chughtai Lab diagnostic center or home-delivered upon request, ensuring seamless access to vital medical information.

AML Expanded Dx (UK) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
FLT3 Gene (ITD/TKD)	Wild-type (No mutation detected)	FLT3-ITD or FLT3-TKD mutation detected; indicates potential for targeted tyrosine kinase inhibitor therapy and adverse prognosis if ITD allelic ratio is high.
NPM1 Gene	Wild-type (No mutation detected)	NPM1 mutation detected; generally associated with a favorable prognosis in the absence of FLT3-ITD mutations.
CEBPA Gene	Wild-type (No mutation detected)	Biallelic (double) CEBPA mutations detected; associated with a highly favorable prognosis and distinct clinical course.
IDH1 & IDH2 Genes	Wild-type (No mutation detected)	IDH1 (R132) or IDH2 (R140/R172) mutation detected; represents actionable targets for specific IDH inhibitors.
TP53 Gene	Wild-type (No mutation detected)	TP53 mutation or deletion detected; strongly associated with complex karyotypes, chemotherapy resistance, and adverse prognosis.
RUNX1 & ASXL1 Genes	Wild-type (No mutation detected)	Mutation detected in RUNX1 or ASXL1; places the patient in the adverse-risk category according to ELN guidelines.
KIT Gene	Wild-type (No mutation detected)	KIT mutation detected; particularly significant in core-binding factor AML, where it may increase relapse risk.
Spliceosome Genes (SRSF2, SF3B1, U2AF1)	Wild-type (No mutation detected)	Mutation detected in one or more spliceosome genes; indicative of secondary AML or myelodysplasia-related changes.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for AML Expanded Dx (UK)?

• Experienced Healthcare Professionals: Our molecular diagnostics division is led by highly qualified, board-certified consultant hematologists and molecular pathologists with extensive experience in leukemia genomics.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the diagnostic journey, offering dedicated support for complex oncology testing.
• Quality Diagnostic Services: Chughtai Lab adheres to stringent international quality control standards, ensuring the highest level of accuracy and reproducibility for molecular assays.
• Professional Reporting: Our comprehensive reports provide detailed clinical interpretations of genetic variants, aligning with the latest WHO and ELN guidelines to assist oncologists in treatment planning.
• Modern Diagnostic Approach: We utilize state-of-the-art next-generation sequencing (NGS) and real-time PCR platforms to deliver precise, high-resolution genomic profiling.
• Comfortable Environment: Our diagnostic centers and collection points across Pakistan are designed to provide a clean, professional, and welcoming environment for patients.
• Convenient Location: With an extensive network of labs and collection centers nationwide, patients can easily access our services, including convenient home sample collection.
• Commitment to Accurate Diagnosis: We understand that timely and accurate molecular profiling is critical for cancer patients, and we are committed to delivering reliable results to guide targeted therapies.